The largest clinical trial ever conducted of MDMA-assisted psychotherapy for post-traumatic stress disorder has reported a 65% remission rate at 12-month follow-up in patients who had failed at least two prior treatment courses — findings published simultaneously in The Lancet Psychiatry and presented at the American Psychiatric Association annual meeting.

The Patient Population

The MAPP3 trial enrolled 412 adults at 14 sites across the United States, Canada, and Australia with chronic PTSD — defined as symptoms persisting for at least one year — who had not achieved remission with two or more prior evidence-based treatments including SSRIs, SNRIs, or prolonged exposure therapy. 67% of participants had military or first-responder trauma; 33% had civilian trauma including assault, childhood abuse, and accident-related PTSD.

The Treatment Protocol

Participants received three experimental sessions, each consisting of MDMA administration (80–120mg) within a structured 8-hour psychotherapy session with two trained therapists, separated by 4-week intervals. All participants also received non-drug psychotherapy preparation sessions (approximately 12 hours total) and integration sessions between MDMA sessions.

The control arm received identical psychotherapy sessions with placebo instead of MDMA — a design that controls for the therapeutic relationship and session structure.

Results at 12 Months

  • 65.3% of MDMA group met criteria for PTSD remission (CAPS-5 score <20) vs 32.1% in control
  • 71.4% of MDMA group showed clinically meaningful improvement (≥12-point reduction in CAPS-5) vs 47.6% in control
  • Remission rates maintained at 18-month follow-up in 91% of initial responders — suggesting durable benefit
  • Functional improvement scores (work, relationships, quality of life) significantly superior in MDMA group

“These patients had been suffering for years and had tried everything available. 65% remission is not incremental progress — it is transformative. PTSD may be one of the first conditions where psychedelic medicine becomes first-line treatment.”

— Dr. Jennifer Mitchell, UCSF Department of Psychiatry, lead investigator

Safety and Side Effects

Adverse events during sessions included transient hypertension (84%), tachycardia (79%), nausea (35%), and anxiety (29%) — all resolving within the session window. No serious cardiovascular events occurred. One case of prolonged psychiatric decompensation occurred in a participant with undisclosed bipolar I disorder — reinforcing the importance of rigorous pre-screening protocols.

Regulatory Status

The FDA rejected a prior NDA for MDMA-assisted therapy in 2024, citing data reliability concerns. The MAPP3 data — which addresses those concerns with enhanced monitoring protocols and independent data verification — is expected to form the basis of a resubmission in mid-2026. Australia has already approved MDMA-assisted therapy for PTSD, making it the first country to do so.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.